Is erbB-2 a predictive marker for response to primary chemotherapy (CT) for operable breast cancer? Prospective study in a phase III randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/Taxol^( !R)(paclitaxel) (AT)

1 Citations

Journal

Citations (1)*help

See more

Details 詳細情報について

  • CRID
    1570572700618300672
  • NII Article ID
    10021288491
  • Data Source
    • CiNii Articles

Report a problem

Back to top